Highly sensitive detection of invasive lung cancer cells by novel antibody against amino-terminal domain of laminin γ2 chain

Kaoru Miyazaki,1,2 Jun Oyanagi,3 Atsuko Sugino,1 Hiroki Sato,1 Tomoyuki Yokose,3 Haruhiko Nakayama4 and Yohei Miyagi2

Key words
Biomarker, laminin γ2, lung cancer, monoclonal antibody, tumor invasion

Correspondence
Kaoru Miyazaki, Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao, Asahi-ku, Yokohama 241-8515, Japan. Tel: +81-45-520-2222; Fax: +81-45-366-3157; E-mail: miyazaki@yokohama-u.ac.jp

Funding Information
Ministry of Education, Culture, Sports, Science and Technology of Japan (23112517 and 23300351).

Received July 25, 2016; Revised September 12, 2016; Accepted September 25, 2016

Cancer Sci 107 (2016) 1909–1918
doi: 10.1111/cas.13089

The basement membrane protein Lm332, a heterotrimer of laminin α3, β3, and γ2 chains, plays critical roles in the structure and function of epithelial tissues.1–3 This laminin was originally identified as an ECM protein secreted by keratinocytes,4,5 and as a cell-scattering factor secreted by human cancer cell lines.6 The strong cell motility activity of Lm332 suggested its possible roles in tumor invasion and metastasis.7–9 As Lm332 is the only laminin containing the Lm-γ2 chain, a number of immunohistochemical studies of various human cancers have been undertaken using anti-γ2 antibodies.9,10 These studies reported that Lm-γ2 is frequently overexpressed at invasion fronts of many types of human cancers of various organs such as the colorectum,11,12 pancreas,13 stomach,14,15–17 esophagus,18 tongue,19 and others.9,10 Many of them showed that the characteristic expression of the Lm-γ2 chain is associated with poor prognosis and metastasis.13,18,19 Moreover, it was found that Lm332 promotes tumor growth in vivo.20–22 Several studies, including ours, have shown that Lm-γ2 is overexpressed as a monomer form in invasive cancer tissues14,16,23 and in cultured cancer cells activated by growth factors.24,25 These findings give rise to the hypothesis that the tumor invasion marker Lm-γ2 may play some active roles in the invasive growth and metastasis of human cancer cells. However, the exact functions of Lm-γ2 in tumor progression are still unclear.

Laminin-γ2 (150 kDa) is cleaved at its short arm by bone morphogenetic protein-1/mammalian tolloid and MMPs, releasing an N-terminal fragment (γ2pf) with 45 kDa as a major proteolytic fragment.7,26–27 This proteolytic processing increases the cell motility activity of Lm332,27,28 but inhibits its matrix assembly.29 It is also known that additional proteolytic cleavages of Lm-γ2 at the C-terminal domain of the short arm (i.e., domain III) by MMPs and elastase generate cell motility fragments.30,31 Laminin γ2pf-like fragments have been found in conditioned media of cultured cancer cells and sera from human cancer patients.32 It was recently found that recombinant proteins of γ2pf and its most N-terminal fragments promote tumor cell invasion and vascular permeability in vivo and in vitro.33,34 CD44 and syndecan-1 are thought to be receptors for the fragments on cancer cells.35,36 These findings support active roles of the N-terminal fragments of Lm-γ2 in cancer progression.

Lung cancer is one of the most common cancers and the leading cause of cancer-related death in many countries.37 The prognosis of patients with lung cancers is generally very
poor. It is critically important for cancer treatments to discriminate invasive carcinomas from non-invasive ones. Laminin-332 is a major component of the bronchioalveolar basement membrane, and Lm-γ2 is often overexpressed in invasive lung cancer tissues. Although past immunohistochemical studies of lung cancers showed the relationship between Lm-γ2 expression and tumor invasiveness, they were unable to show the distribution of Lm-γ2 N-terminal fragments because of the lack of suitable antibodies. In the present study, we prepared mouse mAbs recognizing different regions of γ2pf and investigated the production of γ2 pf N-terminal fragments by various cancer cell lines and its distribution in non-small-cell lung cancers. To show whether the γ2 chain is associated with the α3 and β3 chains in the cancer tissues, localization of the three Lm332 chains was also investigated in detail.

Materials and Methods

Tumor tissues. Human tissue specimens of 29 lung cancers (15 ADCs and 14 SCCs) were obtained from patients who received surgery for lung cancers at the KCC Hospital (Kanagawa, Japan) between 2006 and 2008 for the ADCs and between 2006 and 2009 for the SCCs, and provided by Human Cancer Tissue Bank of KCC. Disease stage was determined according to the TNM classification of the International Union Against Cancer. Histological typing of the tumors was determined according to the 2015 WHO Classification of Tumors. The study protocol was approved by the Ethical Committees of both KCC and Kihara Institute for Biological Research, Yokohama City University (Yokohama, Japan), and carried out according to the guidelines of the 1995 Declaration of Helsinki. Written informed consent was obtained from each patient in the KCC Hospital.

Cell culture. Three human lung carcinoma cell lines (SCC VMRC-LCP, giant cell carcinoma Lu65, and ADC PC5), cervix epidermoid carcinoma line CaSki, three gastric carcinoma lines (MKN-74, MKN-45, and STKM-1), two mammary carcinoma lines (MMK-29 and MDA-MB-231), ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarcinoma line MCAS, and fibrosarcoma line MMK-29 and MDA-MB-231, ovarian mucinous cystadenocarci...
microscopic field (830 × 580 μm) to be scored commonly for the four antibodies was determined as the area showing the highest positive signals with any of the four antibodies. The immunostaining intensity was scored by two observers (K.M. and A.S.) as follows: 0, no or little signal; +1, weak signals; +2, moderate signals; and +3, strong signals. In the tumor cell staining, >50% tumor cells were immunopositive in most cases of the scores of +2 and +3.

**Statistical analysis.** Statistical significance was evaluated with a paired Student’s t-test. A P-value < 0.05 was considered significant.

**Results**

**Analysis of Lm-γ2 N-terminal fragments produced by human cancer cells with a new mAb.** The domain structure of the Lm-γ2 chain is shown in Figure 1. In culture, Lm-γ2 is cleaved predominantly at an N-terminal edge of dIII, releasing a 45-kDa N-terminal fragment (γ2pf) consisting of dV and dIV. Mouse mAbs were prepared using recombinant γ2pf protein as an antigen. Of many antibody clones obtained, one clone that recognizes the second N-terminal EGF-like repeat (NE2) of dV, named clone P2H, was chosen in this study.

To show the metabolism of γ2pf, serum-free conditioned media of human cancer cell lines were analyzed by immunoblotting with the anti-dV antibody P2H. The conditioned medium of lung SCC line VMRC-LCP showed many weak bands in a wide molecular weight range of 15–80 kDa as well as the 45-kDa major band of γ2pf and a 150-kDa minor band of the uncleaved γ2 chain (Fig. 2a). Of these additional bands, the 80-, 22-, and 15-kDa bands appeared to correspond to the whole short arm, the full-length dV, and NE-1/2 or NE2/3, respectively. When analyzed with the anti-dIII antibody D4B5, the immunoblot showed the 105-kDa mature, or processed, γ2 chain (or γ2’) consisting of dII/II and dIII and several minor bands including the 150-kDa and 80-kDa bands. No immunopositive band was detected by D4B5 in a low molecular weight region under 50 kDa. The lung giant cell carcinoma cell line Lu65 showed 22- and 15-kDa dV fragments as analyzed by the anti-dV antibody but only faint bands around 70 kDa by the anti-dIII antibody. We further analyzed the conditioned media of nine cancer cell lines. All these cell lines released significant amounts of small dV fragments in addition to the γ2pf major band (Fig. 2b). In addition, the fragments of 70 and/or 80 kDa were highly detected in MCAS ovarian carcinoma, PC3 lung carcinoma, and HT1080 fibrosarcoma cells.

To identify enzymes responsible for the generation of small γ2 dV fragments, proteinases secreted by three cancer cell lines were analyzed by gelatin zymography (Fig. S1). Based on our past studies, MMP-2, MMP-9, and a low activity of MMP-1 were identified in VMRC-LCP, MCAS, and HT-1080. The presence of the active form of MMP-2 also suggested the expression of MT1-MMP. In addition, soluble forms of matriptase (MT-SP1) were detected as an EDTA-resistant activity in VMRC-LCP and MCAS. When the effects of proteinase inhibitors on the production of dV fragments by VMRC-LCP were examined, a weak but significant inhibition was obtained by the MMP inhibitor TAPI-1 (Fig. S2). The serine proteinase inhibitor aprotinin appeared to slightly inhibit the degradation of the 150-kDa γ2 chain. However, the majority of the dV fragments were not reduced by treatment with these inhibitors, suggesting that they might be intracellularly produced.

We also analyzed whether the dV fragments are produced in lung cancer tissues. When analyzed with the anti-dV antibody P2H, a Triton X-100-soluble fraction from an ADC showed an 80-kDa major band and relatively minor bands of 70, 45, and 22 kDa.
22 kDa, while a Triton X-100-insoluble fraction, which seemed to contain the Lm332 matrix, showed the unprocessed 150-kDa \( \gamma_2 \) chain and many dV-containing fragments (Fig. 2c). Similar results were obtained with a lung SCC but at lower band intensity. These results verified that the 22-kDa fragment, presumably other small dV fragments too, are produced in human lung cancer tissues. The data also indicated that proteolytic cleavage of the Lm-\( \gamma_2 \) chain occurs at C-terminal sites of dIII more frequently \textit{in vivo} than \textit{in vitro} (Fig. 1).

**Distribution of Lm-\( \gamma_2 \) N-terminal fragments in lung ADC tissues.** To show the tissue distribution of Lm-\( \gamma_2 \) N-terminal fragments in non-small-cell lung cancers, serial frozen sections of 15 ADCs and 14 SCCs were subjected to IHC staining with the anti-dV antibody P2H and with the anti-dIII antibody D4B5. These sections were also immunostained with the anti-\( \alpha_3 \) antibody BG5 and the anti-\( \beta_3 \) antibody 12C. Immunopositive signals, which were detected in the cytoplasm of tumor cells, adjacent stroma, and tumor BMs, were scored into four grades (0, +1, +2, and +3).

In a case of a lepidic component of invasive, acinar ADC, non-neoplastic epithelial BMs close to tumor cells were strongly stained with all of the four antibodies, indicating the presence of the Lm332 heterotrimer assembled into the membrane structures (Fig. 3a–d). Although irregular BM-like structures surrounding tumor cells were poorly detected by the anti-dV antibody (Fig. 3a), they were clearly detected by the other three antibodies including the anti-dIII antibody (Fig. 3b–d). In contrast, only the anti-dV antibody clearly stained the cytoplasm of tumor cells. The differential staining patterns between the anti-dV and anti-dIII antibodies suggest that at least a part of the Lm-\( \gamma_2 \) chain is cleaved intracellularly, and \( \gamma_2 \)pf and other dV fragments remain more stably than the processed, 105-kDa \( \gamma_2 \) chain. At an invasion front of the same tumor specimen, where tumor cells had infiltrated stroma, positive signals were found in tumor cells and adjacent stroma intensely with the dV antibody but less markedly with the dIII antibody (Fig. 3e,f). The \( \alpha_3 \) and \( \beta_3 \) chains were faintly detected only on BM-like structures, suggesting that Lm-\( \gamma_2 \) was expressed mostly as a monomer form in this area (Fig. 3g,h). However, in many cases of invasive carcinoma tissues with tumor cells having infiltrated in a scattering manner or collectively into the stroma, these invading tumor cells showed strong cytoplasmic staining for not only \( \gamma_2 \) dV but also the \( \beta_3 \) chain (Fig. 4a–d).

In contrast to the above examples, the cytoplasmic staining of tumor cells for \( \gamma_2 \) dV was only focally obtained in a case of lepidic ADC, where tumor cells were separated by continuous BM structures from the adjacent thick stroma (Fig. 4e–h). In this case, positive signals were found in the stroma for both \( \gamma_2 \) dV and the \( \alpha_3 \) chain, and weakly for \( \gamma_2 \) dIII but scarcely...
for the β3 chain. The stromal overexpression of the γ2 chain was frequently accompanied with that of the α3 chain (Table 1).

**Distribution of Lm-γ2 N-terminal fragments in SCC tissues.** Although SCCs are clearly different from ADCs in their histological characteristics, immunostaining patterns were rather similar to each other. As shown in Figure 5, tumor cells collectively infiltrating stroma with abundant inflammatory cells were stained at the highest level for γ2 dV and moderately for dIII, but weakly or negligibly for β3 and α3, respectively. Tumor BMs were positive for both α3 and β3 but unclear for γ2 dV and dIII. In poorly differentiated carcinomas, the anti-dV antibody well stained both diffusely infiltrating tumor cells and the stroma (Fig. 6a) or tumor cells surrounded by irregular BM-like structures (Fig. 6b). In a moderately differentiated carcinoma, strong signals for γ2 dV were localized on tumor cells at the tumor–stroma interface (Fig. 6c), whereas the tumor cell staining was faint in a well differentiated carcinoma with continuous BM structures (Fig. 6d). In the last case, marked deposition of dV-positive fibrous structures, which were also positive for α3 and β3 (see Table 1), were seen in the stroma adjacent to tumor cells.

All quantitative data shown in Table 1 are summarized in Figure 7. The strong cytoplasmic staining of tumor cells was frequently observed for the γ2 and β3 chains, whereas strong stromal staining was observed for the γ2 and α3 chains. The immunopositive signals in tumor cells and stroma were much higher for γ2 dV than dIII in both ADCs (P = 1 × 10^-4 and 3 × 10^-3, respectively) and SCCs (P = 1 × 10^-3 and 2 × 10^-3, respectively). Although immunoreactivities of tumor BMs were comparable among the four antibodies, those for γ2 dV were significantly lower than those for γ2 dIII (P = 0.01) in ADCs, suggesting that γ2 dV had partially been lost in the Lm332 matrix.

As the present study analyzed only a limited number of tumor samples, we were unable to investigate the relationship between the expression data and the prognosis of cancer patients. However, the strong staining of tumor cells for γ2 dV seemed to correlate with cancer malignancy. The rating of score 3 positivity was 75% in poorly differentiated ADCs, which corresponded to malignancy grade G3, but only 27% in the other tumors (G1 + G2). This was also true in SCCs: 78% for G3 versus 40% for G1 + G2.

**Discussion**

In this study, we prepared a new mAb (clone P2H) against the most N-terminal domain of the γ2 chain (dV). Using this and three other antibodies, we showed the distribution of γ2 short arm fragments and the three Lm332 chains in ADCs and SCCs.
| ADC No. | Stage | Diff. grade† | Tumor cells | Stroma | Tumor BMs | Mean (SD) |
|---------|-------|--------------|-------------|--------|-----------|-----------|
|         |       |              | γ2dV | γ2dIII | α3 | β3 | γ2dV | γ2dIII | α3 | β3 | γ2dV | γ2dIII | α3 | β3 | γ2dV | γ2dIII | α3 | β3 |
| 1       | 1b    | p/d          | 3    | 3      | 0   | 3   | 2    | 2      | 2   | 1   | 0    | 0      | 0   | 0   | 0    | 0      | 0   | 0   |
| 2       | 1a    | w/d          | 1    | 0      | 0   | 1   | 2    | 1      | 2   | 1   | 0    | 1      | 2   | 2   | 0    | 1      | 2   | 2   |
| 3†      | 1b    | m/d          | 0    | 0      | 0   | 0   | 0    | 0      | 2   | 0   | 0    | 0      | 0   | 0   | 0    | 0      | 0   | 0   |
| 4       | 2b    | p/d          | 3    | 2      | 0   | 2   | 2    | 1      | 2   | 1   | 0    | 1      | 2   | 2   | 0    | 1      | 2   | 2   |
| 5       | 1b    | p/d          | 3    | 2      | 0   | 2   | 1    | 0      | 0   | 0   | 0    | 0      | 0   | 0   | 0    | 0      | 0   | 0   |
| 6       | 1a    | m/d          | 3    | 1      | 0   | 1   | 2    | 1      | 1   | 0   | 0    | 1      | 2   | 2   | 0    | 1      | 2   | 2   |
| 7       | 1a    | w/d          | 2    | 0      | 0   | 0   | 1    | 1      | 0   | 0   | 0    | 0      | 0   | 0   | 0    | 0      | 0   | 0   |
| 8       | 1a    | w/d          | 2    | 0      | 0   | 0   | 2    | 1      | 1   | 0   | 0    | 1      | 2   | 2   | 0    | 1      | 2   | 2   |
| 9       | 1a    | w/d          | 2    | 0      | 0   | 0   | 1    | 1      | 0   | 0   | 0    | 1      | 2   | 2   | 0    | 1      | 2   | 2   |
| 10      | 1a    | m/d          | 0    | 0      | 0   | 0   | 3    | 1      | 2   | 0   | 0    | 1      | 2   | 2   | 0    | 1      | 2   | 2   |
| 11      | 1a    | m/d          | 1    | 1      | 1   | 1   | 3    | 1      | 2   | 2   | 1    | 3      | 2   | 2   | 0    | 1      | 2   | 2   |
| 12      | 2b    | m/d          | 2    | 1      | 0   | 1   | 2    | 1      | 1   | 0   | 0    | 1      | 2   | 2   | 0    | 1      | 2   | 2   |
| 13      | 1b    | w/d          | 1    | 0      | 1   | 0   | 1    | 0      | 0   | 0   | 0    | 0      | 0   | 0   | 0    | 0      | 0   | 0   |
| 14      | 2a    | m/d          | 1    | 0      | 0   | 0   | 2    | 1      | 1   | 0   | 0    | 1      | 2   | 2   | 0    | 1      | 2   | 2   |
| 15      | 2a    | m/d          | 3    | 1      | 0   | 0   | 3    | 1      | 1   | 0   | 0    | 1      | 2   | 2   | 0    | 1      | 2   | 2   |

- **SCC No.**
- **Stage**
- **Diff. grade†**
- **Tumor cells**
- **Stroma**
- **Tumor BMs**
- **Mean (SD)**

†w/d (well differentiated), m/d (moderately differentiated), and p/d (poorly differentiated) correspond to the malignancy grades G1, G2 and G3, respectively. †Patients who had recurrence or metastasis within 5 years after surgery.

© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Cancer Sci | December 2016 | vol. 107 | no. 12 | 1914

Original Article

Laminin γ2 N-terminal fragments and tumor invasion
of the lung by IHC. We also showed the metabolism of the γ2 short arm in vitro and in vivo by immunoblotting with these antibodies.

Our immunoblotting data with the anti-dV antibody for the first time revealed that small domain V fragments, as well as the 45-kDa fragment (γ2pF), were produced at high levels by various cultured cancer cell lines. Additionally, the lung cancer tissues contained an 80-kDa fragment as a major component, in addition to γ2pF and small dV fragments. The differential proteolysis between in vitro and in vivo suggests that proteinases expressed by stromal cells, such as activated fibroblasts and inflammatory cells, are also involved in the γ2 chain cleavage. Although further analysis is required, the present study suggested that small dV fragments were at least partly produced intracellularly.

In spite of a number of past IHC studies on Lm-γ2 expression, to our knowledge, none of them investigated the distribution of its N-terminal fragments. In the present IHC study, the dV antibody showed much stronger signals than the dIII antibody in both tumor cells and stroma, although the signal intensity was reversed in tumor BMs. Most of the ADCs and SCCs tested more or less showed immunoreactivity for γ2 dV in the cytoplasm of invasive cancer cells. This immunoreactivity correlated with the malignancy grade of tumors. It is not peculiar that two antibodies recognizing different epitopes of one antigen detect the antigen differently, depending on its molecular states or conformational changes. Indeed, there are reports that some anti-dIII antibodies show poor cytoplasmic reactivity in frozen sections compared to paraffin sections. In the present study, however, the anti-dIII antibody D4B5 produced strong cytoplasmic positivity in some cases of cancer tissues (Table 1). Our results from both immunoblotting and IHC rather suggest that dV fragments remain in tumor cells and stroma more stably than dIII fragments. The experiments with proteinase inhibitors, which suggested the intracellular production of dV fragments, also supports this possibility (Fig. S2). This might allow the anti-dV antibody P2H to detect invasive cancer cells more effectively than the dIII antibody. To the contrary, the γ2 chain of the Lm332 heterotrimer assembled into tumor BMs appears to have mostly been processed releasing its N-terminal fragments. Although positive signals for γ2 dV were strongly detected in the cytoplasm of tumor cells, tumor cells were also shown to secrete dV fragments in vitro, as shown by immunoblotting data. The Lm-γ2 chain or its short

---

Fig. 5. Immunohistochemical staining of poorly differentiated squamous cell carcinoma #6 for γ2 domain V (dV) (a), γ2 dIII (b), α3 (c), and β3 (d). Tumor cells (black arrows) collectively invading stroma show immunoreactivity strongly for dV (a) and moderately for γ2 dIII (b) but poorly for α3 (c) and β3 (d). Basement membrane-like structures (green arrows) are seen for α3 (c) and β3 (d). Insets show an enlarged view of the area shown by a small dashed square (a). Scale bar = 100 μm.

Fig. 6. Immunohistochemical staining of four squamous cell carcinomas with different grades for γ2 domain V (dV). (a) Squamous cell carcinoma (SCC) #9, poorly differentiated; (b) SCC #5, poorly differentiated; (c) SCC #10, moderately differentiated; (d) SCC #4, well differentiated. Strong immunoreactivity (black arrows) is seen in tumor cells infiltrating stroma (a), surrounded by basement membrane-like structures (b) and at the tumor-stroma interface (c), but scarcely in the cells surrounded by continuous basement membrane structures (green arrow) (d). In (d), marked deposition of dV-containing fibrils (black arrow) is seen in the stroma. Insets show enlarged views of the areas shown by small broken squares (a, b, d). Scale bar = 100 μm.
arm stimulates tumor cell invasion in vivo and in vitro,24,33 and recombinant dV fragments promote transendothelial migration of tumor cells in vitro and vascular permeability in vivo.34 We recently found that domain V fragments promote migration of cancer cells by interacting with CD44 on the cell surface.35 Therefore, the accumulation of dV fragments in the tumor microenvironment seems to favor tumor cell invasion and metastasis. The dV fragments are thought to be possible targets to develop new anticancer drugs.

There are some IHC studies that investigated Lm-γ2 expression in lung cancer tissues.15–17,33 Moriya et al. found, using a γ2 dIII antibody, that the cytoplasmic positivity of lung ADC cells for Lm-γ2 is well correlated with poor patient prognosis, although they did not detect the γ2 expression in tumor BMs or stroma.17 This correlation has been confirmed by a recent study.33 The immunostaining patterns of the γ2 expression in the present study are essentially consistent with those reported in past studies with anti-dIII antibodies, but our anti-dV antibody P2H stained invasive tumor cells much more intensely than the anti-dIII antibody D4B5. Our previous study showed frequent overexpression of the Lm-γ2 chain monomer in sclerosing bronchioloalveolar ADC of the lung.16 In agreement with this report, immunostaining with the dV antibody was especially prominent in tumor cells collectively or diffusely infiltrating into desmoplastic fibrous stroma in both ADCs and SCCs. In contrast, the cytoplasmic staining was absent or very poor in tumor cells separated by thick continuous BM structures, although stromal staining was often found in these cases. It seems evident that active interaction between tumor cells and stromal cells induces γ2 expression in tumor cells. In this regard, it should be noted that γ2 expression is associated with epithelial–mesenchymal transition of carcinoma cells, which is induced by transforming growth factor-β, tumor necrosis factor-α, epidermal growth factor, and other soluble factors in vitro.24

Of a number of IHC studies of Lm-γ2 expression, only a few have analyzed the expression of the three Lm332 chains.14,16 In the present study, γ2 signals in tumor cells were often associated with β3 signals, whereas those in tumor stroma were with α3 signals. Franz et al.46 reported that the expression of the Lm-γ2, α3, α4, and α5 chains increases in the stroma of oral SCCs with rising cancer grade. It has been shown that mesenchymal cells contribute to the stromal γ2 expression.47 Our results suggest that the γ2 chain is mainly expressed as its monomer or the β3γ2 heterodimer in lung cancer cells at an invasion front. As no laminin heterotrimers containing the α3 and γ2 chains without the β3 chain have been identified,2 the stromal γ2 chain seems to be mainly expressed as the monomer form. It is possible that the stromal α3 chain exists as Lm321 and/or Lm311 heterotrimers. In any form of Lm-γ2 complexes, N-terminal parts of the γ2 chain seem to be mostly released from the C-terminal core structure.

Immunochemical detection of Lm-γ2 facilitates the assessment of invasiveness and improves diagnostic reproducibility in some types of cancers.48,49 In the present study, we developed for the first time antibodies recognizing the most N-terminal γ2 domain, and one of the anti-dV antibodies detected invasive lung carcinoma cells at a high sensitivity. Such anti-dV antibodies seem useful for the pathological assessment of invasiveness and malignancy in various types of human cancers.

Acknowledgments
We thank Ms Yukako Komori (Kanagawa Cancer Center) and Naoko Watanabe (Yokohama City University) for technical assistance. This work was supported by Grants-in-Aid (23112517 and 23300351) for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Disclosure Statement
The authors have no conflict of interest.

Abbreviations
γ2pf 45-kDa fragment produced by proteolytic cleavage of laminin γ2 chain
ADC adenocarcinoma
BM basement membrane
dIII/dIV/dV domains III/IV/V of laminin γ2 chain
IHC immunohistochemistry
KCC Kanagawa Cancer Center
Lm332 laminin-332
Lm-γ2 laminin γ2
NE N-terminal EGF-like repeat
SCC squamous cell carcinoma
References

1. Colognato H, Yurchenco PD. Form and function: the laminin family of heterotrimers. Dev Dyn 2000; 218: 213–4.
2. Aumailley M, Bruickner-Tuderman L, Carter WG et al. A simplified laminin nomenclature. Matrix Biol 2005; 24: 326–32.
3. Baker SE, Hopkinson SB, Fitchmun M et al. Laminin-5 and hemidesmosomes: role of the alpha3 chain subunit in hemidesmosome stability and assembly. J Cell Sci 1996; 109: 2509–20.
4. Rousselle P, Lunstrum PG, Keene RD et al. Kalinin: an epithelium-specific basement membrane adhesion molecule that is a component of anchoring filaments. J Cell Biol 1991; 114: 1567–76.
5. Carter WG, Ryan MC, Gahr PJ. Epiligrin, a new cell adhesion ligand for integrin alpha 3 beta 1 in epithelial basement membranes. Cell 1991; 65: 599–610.
6. Miyazaki K, Kikwaka Y, Nakamura A et al. A large cell-adhesive scatter factor secreted by human gastric carcinoma cells. Proc Natl Acad Sci USA 1993; 90: 11767–71.
7. Miyazaki K. Laminin-5 (laminin-332): unique biological activity and role in tumor growth and invasion. Cancer Sci 2006; 97: 91–8.
8. Marinkovich MP. Laminin 332 in squamous-cell carcinoma. Nat Rev Cancer 2007; 7: 370–80.
9. Guess CM, Quaranta V. Defining the role of laminin-332 in carcinoma. Matrix Biol 2009; 28: 445–55.
10. Miyazaki K, Sekiguchi K. Laminin-5 in epithelial tumor invasion. J Mol Med 2000; 78: 377–86.
11. Pyke C, Romer J, Kallunki P et al. The gamma 2 chain of laminin/laminin 5 is preferentially expressed in invading malignant cells in human cancers. Am J Pathol 1994; 145: 782–91.
12. Hubek F, Spaderna S, Jung A et al. beta-Catenin activates a coordinated expression of the proufactive factors laminin-5 gamma2 chain and MT1-MMP in colorectal carcinomas. Int J Cancer 2004; 108: 321–6.
13. Takahashi S, Hasebe T, Oda T et al. Cytoplasmic expression of laminin gamma2 chain correlates with postoperative hepatic metastasis and poor prognosis in patients with pancreatic ductal adenocarcinoma. Cancer 2002; 94: 1894–901.
14. Koshikawa N, Moriyama K, Takamura H et al. Overexpression of laminin gamma2 chain monomer in invading gastric carcinoma cells. Cancer Res 1999; 59: 5596–601.
15. Määtä M, Soini Y, Paakko P et al. Expression of the laminin gamma2 chain in different histological types of lung carcinoma. A study by immunohistochemistry and in situ hybridization. J Pathol 1999; 188: 361–8.
16. Kagesato Y, Mizushima H, Koshikawa N et al. Sole expression of laminin gamma2 chain in invading tumor cells and its association with stromal fibrosis in lung adenocarcinomas. Jpn J Cancer Res 2001; 92: 184–92.
17. Moriya Y, Niki T, Yamada T et al. Increased expression of laminin-5 and hemidesmosomes: processes laminin-5 in keratinocytes and skin. J Biol Chem 2003; 278: 15661–8.
18. Giannelli G, Falk-Marzillier J, Schiraldi O et al. Induction of cell migration by matrix metalloproteinase-2 cleavage of laminin-5. Science 1997; 277: 225–8.
19. Ogawa T, Tsubota Y, Maeda M et al. Regulation of biological activity of laminin-5 by proteolytic processing of gamma2 chain. J Cell Biochem 2004; 92: 701–14.
20. Gagnoux-Palacios L, Allegra M, Spiritio F et al. The short arm of the laminin gamma2 chain plays a pivotal role in the incorporation of laminin 5 into the extracellular matrix and in cell adhesion. J Cell Biol 2001; 153: 835–49.
21. Koshikawa N, Giannelli G, Cirulli V et al. Role of cell surface metalloproteinase MT1-MMP in epithelial cell migration over laminin-5. J Cell Biochem 2000; 78: 615–24.
22. Mydel P, Shipley JM, Adair-Kirk TL et al. Neutrophil elastase cleaves laminin-332 (laminin-5) generating peptides that are chemotactic for neutrophils. J Biol Chem 2008; 283: 9513–22.
23. Katayama M, Funakoshi A, Sunmi T et al. Laminin gamma2 chain fragment circu- lating level increases in patients with metastatic pancreatic ductal cell adenocarcinomas. Cancer Lett 2003; 225: 167–76.
24. Moon YW, Rao G, Kim H et al. LAMC2 enhances the metastatic potential of lung adenocarcinoma. Cell Death Differ 2015; 22: 1341–52.
25. Sato H, Oyanagi J, Komiya E et al. Amino-terminal fragments of laminin gamma2 chain retract vascular endothelial cells and increase vascular permeability. Cancer Sci 2014; 105: 168–75.
26. Sato H, Higashi S, Miyazaki K. Amino-terminal fragments of laminin gamma2 chain stimulate migration of metastatic breast cancer cells by interacting with CD44. Clin Exp Metastasis 2015; 32: 405–15.
27. Ogawa T, Tsubota Y, Hashimoto I et al. The short arm of laminin gamma2 chain of laminin-5 (laminin-332) binds syndecan-1 and regulates cellular adhesion and migration by suppressing phosphorylation of integrin beta4 chain. Mol Biol Cell 2007; 18: 1621–33.
28. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7–30.
29. Mizushima H, Koshikawa N, Moriyama K et al. Wide distribution of laminin-5 gamma2 chain in basement membranes of various human tissues. Horm Res 1998; 2: 7–14.
30. Mizushima H, Miyagi Y, Kikwaka Y et al. Differential expression of laminin-5/galectin subunits in human tissues and cancer cell lines and their induction by tumor promoter and growth factors. J Biochem 1996; 120: 1196–202.
31. International Union Against Cancer. TNM Classification of Malignant Tumors, 7th edn. Hoboken, NJ: Wiley-Blackwell, 2009.
32. Travis WD, Brambilla E, Burke AP et al. WHO classification of tumors of the lung, pleura, thymus and heart. In: Bosman FT, Jaffe ES, Lakhanri SR, Ohgaki H, eds. World Health Organization Classification of Tumors. Lyon: IARC Press, 2015.
33. Miyata S, Koshikawa N, Higashi S et al. Expression of trypsin in human cancer cell lines and cancer tissues and its tight binding to soluble forms of Alzheimer amyloid precursor protein in culture. J Biochem 1999; 125: 76–80.
34. Kariya Y, Mori T, Yasuda C et al. Localization of laminin alpha3B chain in vascular and epithelial basement membranes of normal human tissues and its down-regulation in skin cancers. J Mol Histol 2008; 39: 435–46.
35. Shofukuda K, Moriyama K, Nishihashi A et al. Role of tissue inhibitor of metalloproteinases-2 (TIMP-2) in regulation of pro-gelatinase A activation catalyzed by membrane-type matrix metalloproteinase-1 (MT1-MMP) in human cancer cells. J Biochem 1998; 124: 462–70.
36. Jin X, Hirasaki T, Lin C-Y et al. Production of soluble matripase by human cancer cell lines and cell surface activation of its zymogen by trypsin. J Cell Biochem 2005; 95: 632–47.
37. Franz M, Wolheim A, Richter P et al. Stromal laminin chain distribution in normal, hyperplastic and malignant oral mucosa: relation to myofibroblast occurrence and vessel formation. J Oral Pathol Med 2010; 39: 290–8.
38. Franz M, Richter P, Geyer C et al. Mesenchymal cells contribute to the synthesis and deposition of the laminin-5 gamma2 chain in the invasive front of oral squamous cell carcinoma. J Mol Histol 2007; 38: 183–90.
39. Negri G, Romano F, Vittadello F et al. Laminin-5/gamma2 chain immunohistochemistry facilitates the assessment of invasiveness and improves the diagnostic reproducibility of glandular lesions of the cervix uteri. Hum Pathol 2006; 37: 704–10.
40. Driemel O, Dahse R, Hakim SG et al. Laminin-5 immunocytochemistry: a new tool for identifying dysplastic cells in oral brush biopsies. Cytopathology 2007; 18: 348–55.
Supporting Information

Additional Supporting Information may be found online in the supporting information tab for this article:

**Fig. S1.** Analysis of proteinases secreted by VMRC-LCP, MCAS, and HT1080 cells by gelatin zymography.

**Fig. S2.** Effects of serine proteinase and metalloproteinase inhibitors on production of γ2 domain V fragments by VMRC-LCP human lung carcinoma cells.